Abstracts published only.

Then our multivariate analysis showed that NSAID history (OR 4.83; 95% CI, 2.27-10.27; I P i < 0.001), lack of standardization of EFB number (OR 2.99; 95% CI, 1.91-4.68; I P i < 0.001), >= 1.0 cm maximum diameter of the target adenoma (OR 6.18; 95% CI, 1.32-28.99; I P i = 0.021), lobulated shape (OR 2.68; 95% CI, 1.65-4.36; I P i < 0.001), erythema (OR 2.42; 95% CI, 1.50-3.91; I P i < 0.001), erosion (OR 7.12; 95% CI, 3.91-12.94; I P i < 0.001), surface unevenness (OR 2.31; 95% CI, 1.33-4.01; I P i = 0.003) and distal location of the target adenoma (OR 3.29; 95% CI, 1.68-6.41; I P i < 0.001) were significantly associated with the histologically upgrade discrepancies. Colonoscopists could detect more polyps and adenomas with the aid of the CADe (0.90 vs. 0.82, I P i < 0.001; 0.32 vs. 0.30, I P i <0.05), particularly for polyps <5 mm and for flat polyps (0.65 vs. 0.57, I P i < 0.001; 0.74 vs. 0.67, I P i = 0.001, respectively), but the CADe's efficacy could not be reproduced in patients with inadequate bowel preparation and withdrawal time ( I P i = 0.32; I P i = 0.16, respectively). Twenty-six patients suffered from peri-ampullary perforations, fifteen patients suffered from duodenal wall perforations, one patient suffered from a fundus perforation, one patient suffered from a residual gallbladder duct perforation, one patient suffered from a papillary diverticulum perforation, and one patient suffered from an intrahepatic bile duct perforation. The patients were divided into four groups: 19 patients underwent pharmacologic treatment (drug group); 21 patients were treated with EVL (EVL group); 25 patients were treated with PSE (PSE group); and 22 patients underwent EVL plus PSE (EVL + PSE group). [Extracted from the article]